Skip to main content

neuroendocrine tumor Archives

Clinical score can guide PRRT therapy decisions for neuroendocrine tumors

Jan. 19, 2022—A clinical score system developed by researchers at Vanderbilt-Ingram Cancer Center (VICC) has been validated that can guide peptide receptor radionuclide therapy treatment decisions.

Read more


Shifts in neuroendocrine cancer clinical trial design

Nov. 2, 2021—Clinical trials that focus on specific types of neuroendocrine neoplasms — heterogeneous tumors that can occur anywhere in the body — will be more likely to enhance drug development for these tumors, Vanderbilt physicians assert.

Read more


Das lands support for neuroendocrine tumor research

Mar. 5, 2020—Satya Das, MD, has been awarded a $300,000 grant for a two-year period by the Neuroendocrine Tumor Research Foundation.

Read more


Midgut neuroendocrine tumor prognosis

Jan. 6, 2017—Vanderbilt investigators recommend that the presence of tumor deposits in the abdomen be included when staging midgut neuroendocrine tumors.

Read more


Superior scan for tumors

Jun. 24, 2016—Imaging with a compound that binds to neuroendocrine cells is a safer and more effective way to detect rare neuroendocrine tumors.

Read more


Biomarker for intestinal tumors

Oct. 21, 2015—A new marker could be useful for diagnosing and treating neuroendocrine tumors of the small intestines.

Read more


VICC debuts novel neuroendocrine tumor treatment

Apr. 24, 2014—A retired elementary school principal has become the first patient at Vanderbilt-Ingram Cancer Center to receive an investigational cancer therapy for the treatment of his neuroendocrine tumor.

Read more


Recent Stories from VUMC News and Communications Publications

Vanderbilt Medicine
Hope
Momentum
VUMC Voice

more